-
2
-
-
43049098631
-
The diabetic foot: Grand overview, epide-miology and pathogenesis
-
Boulton AJM. The diabetic foot: grand overview, epide-miology and pathogenesis. Diabetes Metab Res Rev 2008; 24 Suppl. 1: S3-6
-
(2008)
Diabetes Metab Res Rev
, vol.24
, Issue.SUPPL. 1
-
-
Boulton, A.J.M.1
-
4
-
-
34547771648
-
The diabetic foot: Established and emerging treatments
-
Papanas N, Maltezos E. The diabetic foot: established and emerging treatments. Acta Clin Belg 2007; 62: 230-238
-
(2007)
Acta Clin Belg
, vol.62
, pp. 230-238
-
-
Papanas, N.1
Maltezos, E.2
-
5
-
-
0345654302
-
Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings
-
Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22: 157-162
-
(1999)
Diabetes Care
, vol.22
, pp. 157-162
-
-
Reiber, G.E.1
Vileikyte, L.2
Boyko, E.J.3
-
6
-
-
2642529778
-
Epidemiology of diabetic foot ulcers and complications: Evidence for prevention
-
Williams R, Herman W, Kinmoth AL, et al., editors Chichester: Wiley
-
Reiber GE, Ledoux WR. Epidemiology of diabetic foot ulcers and complications: evidence for prevention. In: Williams R, Herman W, Kinmoth AL, et al., editors. The evidence base for diabetes care. Chichester: Wiley, 2002: 641-665
-
(2002)
The Evidence Base for Diabetes Care
, pp. 641-665
-
-
Reiber, G.E.1
Ledoux, W.R.2
-
7
-
-
4544221049
-
The diabetic foot: From art to science the 18th Camillo Golgi lecture
-
Boulton AJM. The diabetic foot: from art to science. The 18th Camillo Golgi lecture. Diabetologia 2004; 47: 1343-1353
-
(2004)
Diabetologia
, vol.47
, pp. 1343-1353
-
-
Boulton, A.J.M.1
-
8
-
-
47849085516
-
Becaplermin gel in the treatment of diabetic neuropathic foot ulcers
-
Papanas N, Maltezos E. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin Interv Aging 2008; 3: 233-240
-
(2008)
Clin Interv Aging
, vol.3
, pp. 233-240
-
-
Papanas, N.1
Maltezos, E.2
-
9
-
-
77949871954
-
A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers
-
Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics 2008; 2: 1-12
-
(2008)
Biologics
, vol.2
, pp. 1-12
-
-
Fang, R.C.1
Galiano, R.D.2
-
10
-
-
0032164008
-
Use of Regranex gel for diabetic foot ulcers
-
Piascik P. Use of Regranex gel for diabetic foot ulcers. J Am Pharm Assoc 1998; 38: 628-630
-
(1998)
J Am Pharm Assoc
, vol.38
, pp. 628-630
-
-
Piascik, P.1
-
11
-
-
33847005383
-
Growth factors in the treatment of diabetic foot ulcers: New technologies any promises?
-
Papanas N, Maltezos E. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises? Int J Low Extrem Wounds 2007; 6: 37-53
-
(2007)
Int J Low Extrem Wounds
, vol.6
, pp. 37-53
-
-
Papanas, N.1
Maltezos, E.2
-
12
-
-
77952849087
-
-
US prescribing information for Regranex [online] [Accessed 2010 Mar 16]
-
US prescribing information for Regranex [online]. Available from URL: http://www.regranex.com/Prescribing%20Info. php [Accessed 2010 Mar 16]
-
-
-
-
14
-
-
0028873980
-
Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers
-
Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995; 21: 71-81
-
(1995)
J Vasc Surg
, vol.21
, pp. 71-81
-
-
Steed, D.L.1
-
15
-
-
0031734833
-
Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: A phase III randomized placebo-controlled double-blind study
-
Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21: 822-827
-
(1998)
Diabetes Care
, vol.21
, pp. 822-827
-
-
Wieman, T.J.1
Smiell, J.M.2
Su, Y.3
-
16
-
-
0032399279
-
Effect of so-dium carbomethylcellulose aqueous-based gel versus beca-plermin gel in patients with non-healing lower extremity diabetic ulcers
-
D'Hemercourt PA, Smiell JM, Karim MR. Effect of so-dium carbomethylcellulose aqueous-based gel versus beca-plermin gel in patients with non-healing lower extremity diabetic ulcers. Wounds 1998; 10: 69-75
-
(1998)
Wounds
, vol.10
, pp. 69-75
-
-
D'Hemercourt, P.A.1
Smiell, J.M.2
Karim, M.R.3
-
17
-
-
0033945354
-
Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: An open-label clinical evaluation of safety
-
Embil JM, Papp K, Sibblad G, et al. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of safety. Wound Rep Reg 2000; 8: 162-168
-
(2000)
Wound Rep Reg
, vol.8
, pp. 162-168
-
-
Embil, J.M.1
Papp, K.2
Sibblad, G.3
-
18
-
-
33646115207
-
Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers
-
Margolis DJ, Bartus C, Hoffstad O, et al. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Rep Reg 2005; 13: 531-536
-
(2005)
Wound Rep Reg
, vol.13
, pp. 531-536
-
-
Margolis, D.J.1
Bartus, C.2
Hoffstad, O.3
-
19
-
-
57949103536
-
Which is the better option: Recombinant human PDGF-BB 0.01% gel or standard wound care in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?
-
Bhansali A, Venkatesh S, Dutta P, et al. Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast? Diabetes Res Clin Pract 2009; 83: e13-6
-
(2009)
Diabetes Res Clin Pract
, vol.83
-
-
Bhansali, A.1
Venkatesh, S.2
Dutta, P.3
-
20
-
-
22244469421
-
Efficacy of recombinant human platelet-derived growth factor (rhPDGF) based gel in diabetic foot ulcers: A randomized, multicenter, double-blind, placebo-controlled study in India
-
Hardikar JV, Reddy YC, Bung DD, et al. Efficacy of recombinant human platelet-derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double-blind, placebo-controlled study in India. Wounds 2005; 17: 141-152
-
(2005)
Wounds
, vol.17
, pp. 141-152
-
-
Hardikar, J.V.1
Reddy, Y.C.2
Bung, D.D.3
-
22
-
-
0034529470
-
Risk factors for delayed healing of neuropathic diabetic foot ulcers
-
Margolis DJ, Kantor J, Santanna J, et al. Risk factors for delayed healing of neuropathic diabetic foot ulcers. Arch Dermatol 2000; 136: 1531-1535
-
(2000)
Arch Dermatol
, vol.136
, pp. 1531-1535
-
-
Margolis, D.J.1
Kantor, J.2
Santanna, J.3
-
24
-
-
13444292199
-
Healing Diabetic Neuropathic Foot Ulcers: Are We Getting Better?
-
Margolis DJ, Allen-Taylor L, Hoffstad O, et al. Healing diabetic neuropathic foot ulcers: are we getting better? Diabet Med 2005; 22: 172-176
-
(2005)
Diabet Med
, vol.22
, pp. 172-176
-
-
Margolis, D.J.1
Allen-Taylor, L.2
Hoffstad, O.3
-
25
-
-
0035985215
-
Transforming growth factor-beta 1, 2, 3 and receptor type i and II in diabetic foot ulcers
-
Jude EB, Blakytny R, Bulmer J, et al. Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet Med 2002; 19: 440-447
-
(2002)
Diabet Med
, vol.19
, pp. 440-447
-
-
Jude, E.B.1
Blakytny, R.2
Bulmer, J.3
-
26
-
-
0034028713
-
Lack of insulin-like growth factor 1 (IGF-1) in the basal keratino-cyte layer of diabetic skin and diabetic foot ulcers
-
Blakytny R, Jude EB, Martin Gibson J, et al. Lack of insulin-like growth factor 1 (IGF-1) in the basal keratino-cyte layer of diabetic skin and diabetic foot ulcers. J Pathol 2000; 190: 589-594
-
(2000)
J Pathol
, vol.190
, pp. 589-594
-
-
Blakytny, R.1
Jude, E.B.2
Martin Gibson, J.3
-
27
-
-
0035745275
-
Effect of glycation on basic fibroblast growth factor-induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: Possible relevance to wound healing in diabetes
-
Duraisamy Y, Slevin M, Smith N, et al. Effect of glycation on basic fibroblast growth factor-induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes. Angiogenesis 2001; 4: 277-288
-
(2001)
Angiogenesis
, vol.4
, pp. 277-288
-
-
Duraisamy, Y.1
Slevin, M.2
Smith, N.3
-
28
-
-
0037225778
-
Decrease of collagen deposition in wound repair in type 1 diabetes independent of glycemic control
-
Black E, Vibe-Pedersen J, Jorgensen LN, et al. Decrease of collagen deposition in wound repair in type 1 diabetes independent of glycemic control. Arch Surg 2003; 138: 34-40
-
(2003)
Arch Surg
, vol.138
, pp. 34-40
-
-
Black, E.1
Vibe-Pedersen, J.2
Jorgensen, L.N.3
-
29
-
-
33744780764
-
The molecular biology of chronic wounds and delayed healing in diabetes
-
Blakytny R, Jude E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 2006; 23: 594-608
-
(2006)
Diabet Med
, vol.23
, pp. 594-608
-
-
Blakytny, R.1
Jude, E.2
-
30
-
-
2642543938
-
Wound healing and treatments for people with diabetic foot ulcers
-
Jeffcoate W, Price P, Harding KG. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev 2004; 20 Suppl. 1: S78-89
-
(2004)
Diabetes Metab Res Rev
, vol.1
, Issue.SUPPL.
-
-
Jeffcoate, W.1
Price, P.2
Harding, K.G.3
-
31
-
-
27744448125
-
Wound healing and its impairment in the dia-betic foot
-
Falanga V. Wound healing and its impairment in the dia-betic foot. Lancet 2005; 366: 1736-1743
-
(2005)
Lancet
, vol.366
, pp. 1736-1743
-
-
Falanga, V.1
-
32
-
-
0032720053
-
Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: A combined analysis of four randomized studies
-
Smiell JM, Wieman TJ, Steed DL, et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Rep Reg 1999; 7: 335-346
-
(1999)
Wound Rep Reg
, vol.7
, pp. 335-346
-
-
Smiell, J.M.1
Wieman, T.J.2
Steed, D.L.3
-
33
-
-
0034505166
-
The cost-effective-ness of treating diabetic lower extremity ulcers with beca-plermin (Regranex): A core model with an application using Swedish cost data
-
Persson U, Willis M, Odegaard K, et al. The cost-effective-ness of treating diabetic lower extremity ulcers with beca-plermin (Regranex): a core model with an application using Swedish cost data. Val Health 2000; 3 Suppl. 1: S39-46
-
(2000)
Val Health
, vol.3
, Issue.SUPPL. 1
-
-
Persson, U.1
Willis, M.2
Odegaard, K.3
-
34
-
-
56549089497
-
The cost-effectiveness in the UK of treating diabetic lower extremity ulcers with becaplermin gel
-
Ghatnekar O, Persson U, Willis M, et al. The cost-effectiveness in the UK of treating diabetic lower extremity ulcers with becaplermin gel. J Drug Assess 2000; 3: 243-251
-
(2000)
J Drug Assess
, vol.3
, pp. 243-251
-
-
Ghatnekar, O.1
Persson, U.2
Willis, M.3
-
35
-
-
0034922872
-
Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries
-
Ghatnekar O, Persson U, Willis M, et al. Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001; 19: 767-778
-
(2001)
Pharmacoeconomics
, vol.19
, pp. 767-778
-
-
Ghatnekar, O.1
Persson, U.2
Willis, M.3
-
36
-
-
0035074207
-
Treatment options for diabetic neuropathic foot ulcers: A cost-effectiveness analysis
-
DOI 10.1046/j.1524-4725.2001.00280.x
-
Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001; 27: 347-351 (Pubitemid 32290859)
-
(2001)
Dermatologic Surgery
, vol.27
, Issue.4
, pp. 347-351
-
-
Kantor, J.1
Margolis, D.J.2
-
37
-
-
0036814116
-
Cost-effective management of recalcitrant diabetic foot ulcers
-
Albert S. Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg 2002; 19: 483-491
-
(2002)
Clin Podiatr Med Surg
, vol.19
, pp. 483-491
-
-
Albert, S.1
-
38
-
-
8144226304
-
Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers
-
Sibbald RG, Torrance G, Hux M, et al. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy Wound Manage 2003; 49: 76-84
-
(2003)
Ostomy Wound Manage
, vol.49
, pp. 76-84
-
-
Sibbald, R.G.1
Torrance, G.2
Hux, M.3
-
39
-
-
77952793213
-
Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer
-
Lantis II JC, Boone D, Gendics C, et al. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer. Adv Skin Wound Care 2009; 22: 167-171
-
(2009)
Adv Skin Wound Care
, vol.22
, pp. 167-171
-
-
Lantis Ii, J.C.1
Boone, D.2
Gendics, C.3
-
40
-
-
0031713762
-
Clinical safety of becaplermin (rhPDGF-BB) gel
-
Smiell JM. Clinical safety of becaplermin (rhPDGF-BB) gel. Am J Surg 1998; 176 Suppl. 2A: 68-73S
-
(1998)
Am J Surg
, vol.176
, Issue.SUPPL. 2A
-
-
Smiell, J.M.1
-
41
-
-
77952796728
-
Efficacy and safety of recombinant human platelet-derived growth factor gel for diabetic neuropathic foot ulcers: A systematic review
-
Shi J, Chen T, Tian H. Efficacy and safety of recombinant human platelet-derived growth factor gel for diabetic neuropathic foot ulcers: a systematic review. Diabetologia 2009; 52 Suppl. 1: A1157
-
(2009)
Diabetologia
, vol.52
, Issue.SUPPL. 1
-
-
Shi, J.1
Chen, T.2
Tian, H.3
-
42
-
-
85049141358
-
-
Update of safety review: follow-up to the March 27 [online] [Accessed 2009 Oct 7]
-
US FDA. Update of safety review: follow-up to the March 27, 2008, communication about the ongoing safety review of Regranex (becaplermin) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/DrugSafetyIn formationforHeathcareProfessionals/ucm072148.htm [Accessed 2009 Oct 7]
-
(2008)
Communication about the Ongoing Safety Review of Regranex (Becaplermin)
-
-
Us, F.D.A.1
-
43
-
-
33750956014
-
Emerging drugs for diabetic foot ulcers
-
Petrova N, Edmonds M. Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs 2006; 11: 709-724
-
(2006)
Expert Opin Emerg Drugs
, vol.11
, pp. 709-724
-
-
Petrova, N.1
Edmonds, M.2
-
44
-
-
77952795360
-
Topical becaplermin: Cancer. Think twice before using it
-
Topical becaplermin: cancer. Think twice before using it. Rev Prescrire 2008; 28: 430
-
(2008)
Rev Prescrire
, vol.28
, pp. 430
-
-
|